Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Fineline Cube Jul 16, 2026
Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Fineline Cube Jul 16, 2026
Company Deals

Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development

Fineline Cube May 30, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...

Company Deals

Danaher Partners with AstraZeneca to Advance Precision Medicine

Fineline Cube May 30, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...

Company Drug

Innovent Biologics Doses First Patient in Phase III Psoriasis Trial for Picankibart

Fineline Cube May 30, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first subject dosing in a Phase III...

Company Drug

GSK Halts PIVOT-PO Trial Early as Tebipenem HBr Meets Efficacy Targets for cUTI

Fineline Cube May 30, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase...

Company Drug

Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency

Fineline Cube May 30, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...

Company Drug

Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD

Fineline Cube May 30, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...

Company Deals

Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship

Fineline Cube May 30, 2025

China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...

Company Deals

GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation

Fineline Cube May 29, 2025

Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD...

Company Medical Device

Abbott Laboratories Receives FDA Approval for Tendyne TMVR System

Fineline Cube May 29, 2025

US-based medical device giant Abbott Laboratories (NYSE: ABT) announced that it has received marketing approval...

Company Deals

AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy

Fineline Cube May 29, 2025

Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...

Company Drug

BMS Gains European Approval for Opdivo Subcutaneous Formulation

Fineline Cube May 29, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to...

Company Drug

Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China

Fineline Cube May 29, 2025

The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical...

Company Drug

InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248

Fineline Cube May 29, 2025

Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical...

Company Deals

Fosun Pharma and Jiuyuan Gene Partner to Commercialize Biologics in Global Markets

Fineline Cube May 29, 2025

Chinese pharmaceutical firms Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Hangzhou...

Company Drug

Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma

Fineline Cube May 29, 2025

Guangzhou Lupeng Pharmaceutical Co., Ltd’s rocbrutinib is currently under New Drug Application (NDA) review at...

Company Deals

Viva Biotech Establishes RMB 300M Fund for Early-Stage Pharma Projects

Fineline Cube May 29, 2025

China-based Contract Research Organization (CRO) Viva Biotech (HKG: 1873) announced that its wholly-owned subsidiary, Hangzhou...

Company Drug

Bayer’s Sevabertinib Receives FDA Priority Review for HER2-mutant NSCLC

Fineline Cube May 29, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its investigational oral small-molecule tyrosine kinase...

Company Drug

JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL

Fineline Cube May 29, 2025

JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...

Company Medical Device

Sino Medical Sciences Technology’s AUCURA Flow-Diverting Stent Approved by NMPA

Fineline Cube May 29, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its holding subsidiary Neurovita has...

Company Drug

Changchun Pharma Wins FDA Approval for GenSci128 in TP53 Y220C Solid Tumors

Fineline Cube May 29, 2025

China-based Changchun High & New Technology Industries (Group) Inc., (SHE:000661) announced that its subsidiary Changchun...

Posts pagination

1 … 182 183 184 … 695

Recent updates

  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
  • Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
  • Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
  • China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
  • Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Company Drug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

Company Drug

China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.